PFF In The Media

Inhaled treprostinil lowers FVC decline in IPF at 52 weeks

With receipt of inhaled treprostinil for 52 weeks, adults with idiopathic pulmonary fibrosis had less FVC decline compared with those receiving placebo, according to results published in The New England Journal of Medicine.

Link to Article

St. Luke’s designated as pulmonary center

St. Luke's University Health Network has been designated as a Care Center within the Pulmonary Fibrosis Foundation's nationally recognized Care Center Network, expanding access to specialized care for people living pulmonary fibrosis and interstitial lung disease in the region.

Link to Article

Pulmonary Fibrosis Foundation expands national care network, strengthening access to expert lung disease care

The Pulmonary Fibrosis Foundation’s Care Center Network has grown to include 96 sites in 40 states as part of its first expansion since 2023, marking a milestone in strengthening access to multidisciplinary care for people living with pulmonary fibrosis (PF) and interstitial lung disease (ILD).

Link to Article

Partner with PFF through advocacy and education to benefit PF community

The third pillar of 5-year strategic plan focuses on improving patients' lives

Link to Article

Christine Ebersole, Jelani Alladin and More to Star in BROADWAY BELTS FOR PFF!

The lineup has been revealed for the 16th annual Broadway Belts for PFF! on Monday, March 9, at SONY Hall with a simultaneous virtual livestream.

Link to Article

Q&A: FDA accepts IPF biomarker panel into qualification program

The FDA Center for Drug Evaluation and Research has accepted a letter of intent for the first biomarker for idiopathic pulmonary fibrosis into its Biomarker Qualification Program, according to a press release.

Link to Article

Extended-release nalbuphine lowers cough frequency in IPF-associated chronic cough

Patients with idiopathic pulmonary fibrosis-associated chronic cough who received twice-daily oral extended release nalbuphine for 6 weeks had decreases in 24-hour cough frequency, according to data published in JAMA.

Link to Article

How the PFF’s 5-year plan seeks to expand access to expert care

I’ve been writing recently about the four pillars of the Pulmonary Fibrosis Foundation’s (PFF) new five-year strategic plan introduced last year, called “The PFF Is ME.” In December, I explained the first pillar, Accelerate Research. The second pillar, Expand Access to Expert Care, is a concern for all patients in the pulmonary fibrosis (PF) community. I had the opportunity to interview the champion of the plan’s second pillar, Sonye Danoff, MD, PhD, the senior medical adviser for the PFF’s Care Center Network (CCN).

Link to Article

A first for IPF biomarkers: PROLIFIC risk score nears FDA qualification

The PROLIFIC Risk Score, a multi-biomarker blood test for idiopathic pulmonary fibrosis (IPF), has taken a significant step forward in regulatory recognition. In December 2025, the FDA’s Center for Drug Evaluation and Research accepted PROLIFIC’s Letter of Intent into its Biomarker Qualification Program; the first time an IPF biomarker has reached this milestone. This step underscores the potential of the Risk Score to improve how patients are stratified in clinical trials and how disease progression is predicted, addressing a key challenge in IPF drug development and patient care.

Link to Article

1World Radio Episode 89 - Julie Halston

Learn about Julie Halston and her late husband Ralph Howard's journey with pulmonary fibrosis, the work of the Pulmonary Fibrosis Foundation and Julie's annual event Broadway Belts for PFF. For more information about the Pulmonary Fibrosis Foundation you can go to https://www.pulmonaryfibrosis.org

Link to Article

Angiotensin-converting enzyme inhibitor use before IPF diagnosis lowers mortality risk

Chronic fatigue is a common symptom of idiopathic pulmonary fibrosis (IPF), and may affect as many as 95 percent of all individuals living with this condition. Fatigue can have a significant impact on quality of life, and it generally stems from several factors including difficulty breathing, disrupted sleep, anxiety and depression, and medications used to treat IPF.

Link to Article

6 Tips for Managing Chronic Fatigue with IPF

Chronic fatigue is a common symptom of idiopathic pulmonary fibrosis (IPF), and may affect as many as 95 percent of all individuals living with this condition. Fatigue can have a significant impact on quality of life, and it generally stems from several factors including difficulty breathing, disrupted sleep, anxiety and depression, and medications used to treat IPF.

Link to Article

DOD-funded study explores metformin as potential therapy for IPF

A clinical study led by Fernando Martinez, M.D., vice chair for clinical and translational research and academic chief of the Division of Pulmonary, Allergy and Critical Care at UMass Chan Medical School and funded by the Department of Defense (DOD) is targeting idiopathic pulmonary fibrosis (IPF).

Link to Article

4 Hidden IPF Triggers in Your Living Space

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease that causes scarring (fibrosis) of the lungs. The most common symptoms are shortness of breath and cough, and the progression of the disease varies considerably from person to person.

Link to Article

5 Ways to Manage Breathlessness and Anxiety in IPF

Breathlessness (also known as dyspnea) and anxiety are common symptoms experienced by individuals with idiopathic pulmonary fibrosis (IPF). They are also linked together in a “dyspnea-anxiety cycle.” Feeling short of breath can trigger anxiety, which can worsen your breathing and make you feel even more breathless.

Link to Article

From Her New Mexico Home, Karen Smoot Advocates for Fellow Patients With IPF

Trim and athletic her entire life, Karen Smoot—a nonsmoker—was still running triathlons in her early 60s. That’s why she was surprised when, in 2011, she began having trouble walking up to the fourth floor of the office where she worked.

Link to Article

ILD Pulmonary Care Outcomes Don’t Depend on Distance

Individuals in close proximity to care for interstitial lung disease (ILD) did not have significantly improved outcomes than those at a greater distance, based on data from more than 1600 individuals and presented at American College of Chest Physicians (CHEST) 2025 Annual Meeting.

Link to Article

Small changes in lung CT scans linked to declining lung function

Whether change in fibrosis on high-resolution CT is associated with near- and longer-term outcomes in patients with fibrotic interstitial lung disease (fILD) remains unclear, prompting a new study by researchers led by Matthew Koslow, M.D., of the Center for Interstitial Lung Disease, Division of Pulmonary and Critical Care Medicine at National Jewish Health in Denver, and colleagues.

Link to Article